REVIEW PAPER
Immunomodulation on the ocular surface: a review
Submission date: 2016-01-31
Acceptance date: 2016-02-29
Publication date: 2016-07-15
Cent Eur J Immunol 2016;41(2):195-208
KEYWORDS
ABSTRACT
The increasing understanding of immune mechanisms changed our perception of the ocular surface, which is now considered a compartment of the common mucosal immune system. It offered the possibility to alter the physiological immune response on the ocular surface and effectively combat inflammation, which impairs stability of the tear film and causes tear hyperosmolarity, causing symptoms of dry eye disease. The paper provides an overview of ocular surface anatomy and physiology, explains the underlying mechanisms of dry eye disease and discusses novel and promising treatment modalities, such as cyclosporine A, biological therapies using autologous serum and various growth factors as well as experimental treatment methods which are currently being investigated.
REFERENCES (81)
1.
Radomska-Leśniewska DM, Skopiński P, Bałan BJ, et al. (2015): Angiomodulatory properties of Rhodiola spp. and other natural antioxidants. Centr Eur J Immunol 40: 249-262.
2.
Rokicki D, Zdanowski R, Lewicki S, et al. (2014): Inhibition of proliferation, migration and invasiveness of endothelial murine cells culture induced by resveratrol. Centr Eur J Immunol 39: 449-454.
3.
Thoft RA, Friend J (1977): Biochemical transformation of regenerating ocular surface epithelium. Invest Ophthalmol Vis Sci 16: 14-20.
4.
Ambroziak AM, Krawczyk P, Skopiński P (2013): Zaburzenia powierzchni oka w ujęciu immunologicznym ze szczególnym uwzględnieniem spojówki i nabłonka rogówki. Kontaktologia i Optyka Okulistyczna 1: 16-19.
5.
Skopiński P, Krawczyk P, Ambroziak AM (2013): Immunology of the ocular surface and contact lens wear: theoretical fundamentals. Centr Eur J Immunol 38: 254-259.
6.
Ambroziak AM, Krawczyk P, Szulborski K, Skopiński P (2013): Clinical implications of the immunity of the ocular surface: the effect of extended contact lens wear. Centr Eur J Immunol 38: 260-264.
7.
Barabino S, Chen Y, Chauhan S, Dana R (2012): Ocular Surface Immunity: Homeostatic Mechanisms and Their Disruption in Dry Eye Disease. Progress in Retinal and Eye Research 31: 271-285.
8.
Knop E, Knop N (2007): Anatomy and immunology of the ocular surface. Chem Immunol Allergy 92: 36-49.
9.
Knop E, Knop N (2000): Conjunctiva-associated lymphoid tissue in the human eye. Invest. Ophthalmol Vis Sci 41: 1270-1279.
10.
Knop E, Knop N (2005): The role of eye-associated lymphoid tissue in corneal immune protection. J Anatom 206: 271-285.
11.
Seamone C, Jackson WB (2013): Immunology of the External Eye. In: Tasman W, Jagger EA (eds.). Duane’s Clinical Ophthalmology. Vol. 4 Ch. 2, Lippincott-Raven, Philadelphia.
12.
Knop E, Knop N, Claus P (2008): Local production of secretory IgA in the eye-associated lymphoid tissue (EALT) of the normal human ocular surface. Invest Ophthalmol Vis Sci 49: 2322-2329.
13.
Gibson IK, Kunert KS, Argüeso P (2000): Regulation of mucin gene expression in the ocular surface epithelia. Cornea 19: 97.
14.
Rolando M, Zierhut M (2001): The ocular surface and tear film and their dysfunction in dry eye disease. Surv Ophthalmol 45: 203-210.
15.
Watanabe H (2002): Significance of mucin on the ocular surface. Cornea 21: 17-22.
16.
Dartt DA, Dana R, D’amore P, et al. (2011): Immunology, inflammation and diseases of the eye. Elsevier, Groton.
17.
Stern ME, Beuerman RW, Fox RI, et al. (1998): The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 17: 584-589.
18.
Stern ME, Schaumburg CS, Pflugfelder SC (2013): Dry Eye as a mucosal autoimmune disease. Int Rev Immunol 32: 19-41.
19.
Beuerman RW, et al. (2004): The Lacrimal Functional Unit in Dry Eye and Ocular Surface Disorders. Pflugfelder SC, Beuerman RW, Stern ME (eds.). Marchel Dekker, New York, 11-39.
20.
Lemp MA, et al. (2012): Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: a retrospective study. Cornea 31: 472-478.
22.
Nichols K (2011): The International Workshop on Meibomian Gland Dysfunction: Introduction. IOVS 52: 1917-1921.
23.
Nichols KK, Foulks GN, Bron AJ, et al. (2011): The International Workshop on Meibomian Gland Dysfunction: Executive Summary. Invest Ophthalmol Vis Sci 30; 52: 1922-1929.
24.
Bron AJ, Benjamin L, Snibson GR (1991): Meibomian gland disease. Classification and grading of lid changes. Eye 5: 395-411.
25.
Mathers W, Shields W, Sachdev M, et al. (1991): Meibomian gland dysfunction in chronic blepharitis. Cornea 10: 277-285.
26.
Yokoi N, Mossa F, Tiffany JM, Bron AJ (1999): Assessment of meibomian gland function in dry eye using meibometry. Arch Ophthalmol 117: 723-729.
27.
Geerling G, Tauber J, Baudouin C, et al. (2011): The international workshop on meibomian gland dysfunction: report of the subcommittee on management and treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 2011; 52: 2050-2064.
28.
Korb DR, Henriquez AS (1980): Meibomian gland dysfunction and contact lens intolerance. J Am Optom Assoc 51: 243-251.
29.
Survase SA, Kagliwal LD, Annapure US, Singhal RS (2011): Cyclosporin A – a review on fermentative production, downstream processing and pharmacological applications. Biotechnology Advances 29: 418-435.
30.
Hunter PA, Wilhelmus KR, Rice NSC, et al. (1981): Cyclosporin A applied topically to the recipient eye inhibits corneal graft rejection Clin Exp Immunol 45: 173-177.
31.
Summary of Product Characteristics. Restasis® ophthalmic emulsion 0.5 mg/mL (2012), Allergan.
32.
Daull P, Lallemand F, Philips B, et al. (2011): Distribution of cyclosporin A in ocular tissues after topical administration of cyclosporin A-cationic emulsion to pigmented rabbits. IOVS; 186: 376.
33.
Kaswan RL (1988): Intraocular penetration of topically applied cyclosporin. Transplantation Proceedings 20 (suppl.): 650-655.
34.
Lallemand F, Felt-Baeyens O, Besseghir K, et al. (2003): Cyclosporin A delivery to the eye: a pharmaceutical challenge. Eur J Pharmaceutics Biopharmaceutics 56: 307-318.
35.
Yokoi N (2013): Dry eye syndrome: basic and clinical perspectives. Future Medicine Ltd, UK, doi: 10.2217/9781780842646.
36.
Summary of Product Characteristics. Ikervis® 1 mg/ml eye drops, emulsion. (2015) Santen UK Limited.
37.
Stevenson W, Chauhan SK, Dana R (2012): Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 130: 90-100.
38.
Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. (2006): Efficacy of commercially available topical cyclosporin A 0.05% in the treatment of meibomian gland dysfunction. Cornea 25: 171-175.
39.
Perry HD, Doshi S, Donnenfeld ED, et al. (2003): Double Masked Randomized Controlled Study Evaluating Topical 0.05% Cyclosporin A in the Treatment of Meibomian Gland Dysfunction (Posterior Blepharitis). IOVS; 44: 1395.
40.
Lallemand F, Daull Ph, Benita S, et al. (2012): Successfully Improving Ocular Drug Delivery Usingthe Cationic Nanoemulsion, Novasorb. J Drug Delivery 2012: 604204.
41.
Buggage RR, Amrane M, Ismail D, et al. (2011): The effect of Cyclokat (unpreserved 0.1% cyclosporin cationic emulsion) on corneal involvement in patients with moderate to severe dry eye disease participating in a phase III, multicenter, randomized, controlled, double-masked, clinical trial. Eur J Ophthalmol doi: 10.5301/EJO.2011.7544.
42.
Leonardi A (2015): Ikervis® 1 mg/ml cyclosporin – a new therapeutic option for the treatment of severe keratitis in dry eye disease. Changing paradigms of treating severe keratitis in dry eye disease – ocular surface symposium report. Proceedings of a Symposium Presented at the European Society of Ophthalmology 2015 Congress in Vienna, Austria on 7 June.
43.
Gupta C, Chauhan A (2011): Ophthalmic delivery of cyclosporin A by punctal plugs. J Controlled Release 150: 70-76.
44.
Summary of Product Characteristics. Prograf®: tacrolimus capsules, tacrolimus injection for intravenous infusion only (2009). Astellas Pharma US, Inc.
45.
Moscovici BK, Holzchuh R, Sakassegawa-Naves FE, et al. (2015): Treatment of Sjögren’s syndrome dry eye using 0.03% tacrolimus eye drop: Prospective double-blind randomized study. Contact Lens and Anterior Eye 38: 373-378.
46.
NCT00814944 Study Record Detail (2016). Available at: clinicaltrials.gov (Access: 2016, January 23).
47.
Colligris B, Crooke A, Huete-Toral F, Pintor J (2014): An update on dry eye disease molecular treatment: advances in drug pipelines. Expert Opinion on Pharmacotherapy 15: 1371-1375.
48.
Dogru M, Tsubota K (2011): Pharmacotherapy of dry eye. Expert Opin. Pharmacother 12: 325-334.
49.
Quinto GG, Campos M, Behrens A (2008): Autologous serum for ocular surface diseases. Arq Bras Oftalmol 71 (6 Suppl): 47-54.
50.
Ralph RA, Doane MG, Dohlman CH (1975): Clinical experience with a mobile ocular perfusion pump. Arch Ophthalmol 93: 1039-1043.
51.
Fox RI, Chan R, Michelson JB, et al. (1984): Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum 27: 459-461.
52.
Tsubota K, Goto E, Shimmura S, et al. (1999) Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology 106: 1984-1989.
53.
Management and therapy of dry eye disease: report of the Management and Therapy Subcommittee of the International Dry Eye WorkShop (2007). 2007; 5: 163-178.
54.
Bradley JC, Bradley RH, McCartney DL, Mannis MJ (2008): Serum growth factor analysis in dry eye syndrome. Clin Experiment Ophthalmol 36: 717-720.
55.
Pan Q, Angelina A, Zambrano A, et al. (2013): Autologous serum eye drops for dry eye. Cochrane database 8: CD009327; doi:10.1002/14651858.CD009327.pub2.
56.
Geerling G, MacLennan S, Hartwig D (2004): Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol 88: 1467-1474.
57.
Anitua E, de la Fuente M, Muruzabal F, et al. (2015): Plasma rich in growth factors (PRGF) eye drops stimulates scarless regeneration compared to autologous serum in the ocular surface stromal fibroblasts. Experimental Eye Research 135: 118-126.
58.
Wróbel-Dudzińska D, Pyszniak E, Kuna A, et al. (2014): Produkty krwiopochodne w leczeniu zespołu suchego oka. Okulistyka (2014): 69-71.
59.
Geerling G, Hartwig D (2006): Autologous serum eyedrops for ocular surface disorders. In: Reinhard T, Larkin DFP (eds.). Essentials in Ophthalmology: Cornea and External Eye Disease. Springer Berlin Heidelberg New York, 1-20.
61.
Amparo F, Dastjerdi MH, Okanobo A, et al. (2013): Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 131: 715-723.
63.
Xiao X, He H, Lin Z, et al. (2012): Therapeutic effects of epidermal growth factor on benzalkonium chloride-induced dry eye in a mouse model. Invest Ophthalmol Vis Sci 53: 191-197.
64.
De Paiva CS, Volpe EA, Gandhi NB, et al. (2011): Disruption of TGF- signaling improves ocular surface epithelial disease in experimental autoimmune keratoconjunctivitis sicca. PLoS ONE 6: e29017. doi: 10.1371/journal.pone.0029017.
65.
Lambiase A, Mantelli F, Sacchetti M, et al. (2011): Clinical applications of NGF in ocular diseases. Arch Ital Biol 149: 283-292.
66.
Bonini S, Aloe L, Bonini S, et al. (2002): Nerve growth factor (NGF): an important molecule for trophism and healing of the ocular surface. Adv Exp Med Biol 506 (Pt A): 531-537.
67.
Ferrari MP, Mantelli F, Sacchetti M, et al. (2014): Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs 28: 275-283.
68.
Ma K, Yan N, Huang Y, et al. (2014): Effects of nerve growth factor on nerve regeneration after corneal nerve damage. Int J Clin Experimental Med 7: 4584-4589.
69.
Sacchetti M, Lambiase A (2014): Diagnosis and management of neurotrophic keratitis. Clinical Ophthalmology 8: 571-579.
70.
Viiri J, Jauhonen HM, Kauppinen A, et al. (2009): Cis-urocanic acid suppresses UV-B-induced interleukin-6 and -8 secretion and cytotoxicity in human corneal and conjunctival epithelial cells in vitro. Molecular Vision 15: 1799-1805.
71.
Jauhonen HM, Kari E, Pylkkänen L, et al. (2015): A randomized phase I clinical study of cis-urocanic acid eye drops in healthy adult subjects. Acta Ophthalmol doi: 10.1111/aos.12651.
72.
Leino L, Jauhonen H, Kari E, et al. (2012): Cis-urocanic acid eye drops are safe and well tolerated in healthy adults – results from a randomised phase 1 clinical study. Acta Ophthalmologica 90; doi: 10.1111/j.1755-3768.2012.T104.x.
73.
NCT02326090 Study Record Detail, clinicaltrials.gov, accessed on January 23 (2016).
74.
Herantis Pharma Plc. Company media release dated 3 June (2015), accessed on January 23, 2016.
75.
Tauber J, Karpecki P, Latkany R, et al. (2015): Lifitegrast ophthalmic solution 5.0% versus placebo for treatment of dry eye disease. Ophthalmology 122: 2423-2431.
76.
Shire plc. Company media release dated October 27 (2015), accessed on January 23, 2016.
77.
Bielecka A, Ambroziak AM, Skopiński P, et al. (2011): Zastosowanie kortykosteroidów w okulistyce. Kontaktologia i Optyka Okulistyczna 1: 7-10.
78.
Langwińska-Wośko E, Bielecka A, Ambroziak AM, et al. (2011): Niesteroidowe leki przeciwzapalne w okulistyce. Okulistyka 3: 17-20.
79.
Dursun Altnörs D, Suveren E, Karabay Ü, Aydn Akova Y (2010): Effects of human breast-milk on corneal epithelial healing in a in vitro model. AAO&MEACO 2001, Chicago.
80.
Enríquez-de-Salamanca A, Castellanos E, Stern ME, et al. (2010) Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. Mol Vis 16: 862-873.
81.
Li S, Sack R, Vijmasi T, et al. (2008): Antibody protein array analysis of the tear film cytokines. Optom Vis Sci 85: 653-660.
| eISSN: | 1644-4124 |
| ISSN: | 1426-3912 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
